Durvalumab monotherapy is the first-line treatment for unresectable stage III non-small cell lung cancer following platinum-based chemoradiotherapy (specific to PD-L1 positive patients in the European Union). The gene discussed is CD274; the disease is non-small cell lung carcinoma.